MedTrace Logo

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

NCT04852666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 465

Last updated 2024-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess effectiveness of vedolizumab versus ustekinumab in patients with Crohn's disease and vedolizumab versus tofacitinib in patients with ulcerative colitis, after non-response to anti-tumor necrosis factor (TNF) medications, using data from two existing cohorts.

Conditions

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    lead OTHER

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Crohn's and Colitis Foundation

    collaborator OTHER

Principal Investigators

  • Michael Kappelman, MD · University of North Carolina, Chapel Hill

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-25
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04852666 on ClinicalTrials.gov